Related Experiment Video
Updated: Nov 3, 2025
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
Published on: August 10, 2017
8a, a New Acridine Antiproliferative and Pro-Apoptotic Agent Targeting HDAC1/DNMT1
Qiting Zhang1, Ziyan Wang2, Xinyuan Chen2
1Institute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China.
Abstract:
Epigenetic therapy using histone deacetylase (HDAC) inhibitors has become an attractive project in new drug development. However, DNA methylation and histone acetylation are important epigenetic ways to regulate the occurrence and development of leukemia. Given previous studies, N-(2-aminophenyl)benzamide acridine (8a), as a histone deacetylase 1 (HDAC1) inhibitor, induces apoptosis and shows significant anti-proliferative activity against histiocytic lymphoma U937 cells. HDAC1 plays a role in the nucleus, which we confirmed by finding that 8a entered the nucleus. Subsequently, we verified that 8a mainly passes through the endogenous (mitochondrial) pathway to induce cell apoptosis. From the protein interaction data, we found that 8a also affected the expression of DNA methyltransferase 1 (DNMT1). Therefore, an experiment was performed to assess the binding of 8a to DNMT1 at the molecular and cellular levels. We found that the binding strength of 8a to DNMT1 enhanced in a dose-dependent manner. Additionally, 8a inhibits the expression of DNMT1 mRNA and its protein. These findings suggested that the anti-proliferative and pro-apoptotic activities of 8a against leukemia cells were achieved by targeting HDAC1 and DNMT1.
Insights
N-(2-aminophenyl)benzamide acridine (8a) targets both histone deacetylase 1 (HDAC1) and DNA methyltransferase 1 (DNMT1) to inhibit leukemia cell proliferation and induce apoptosis. This dual epigenetic targeting offers a promising strategy for leukemia treatment.
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Research
Background:
- Epigenetic modifications, including DNA methylation and histone acetylation, are crucial in regulating leukemia development.
- Histone deacetylase (HDAC) inhibitors are a key area in novel drug development for cancer therapy.
Purpose of the Study:
- To investigate the anti-leukemic effects of N-(2-aminophenyl)benzamide acridine (8a), a novel histone deacetylase 1 (HDAC1) inhibitor.
- To elucidate the molecular mechanisms underlying the anti-proliferative and pro-apoptotic activities of 8a in leukemia cells.
Main Methods:
- Cellular assays to assess anti-proliferative and apoptotic effects in U937 lymphoma cells.
- Confocal microscopy to confirm nuclear localization of 8a.
- Western blotting and RT-PCR to analyze the expression of HDAC1 and DNA methyltransferase 1 (DNMT1) and their mRNA.
- Molecular binding assays to evaluate the interaction between 8a and DNMT1.
Main Results:
- Compound 8a demonstrated significant anti-proliferative activity and induced apoptosis in U937 cells.
- 8a was confirmed to enter the nucleus and primarily induce apoptosis via the mitochondrial pathway.
- Protein interaction data revealed that 8a affects DNMT1 expression.
- Molecular and cellular experiments showed dose-dependent binding of 8a to DNMT1, inhibiting its mRNA and protein expression.
Conclusions:
- The anti-leukemic effects of 8a are attributed to its dual inhibition of HDAC1 and DNMT1.
- Targeting both HDAC1 and DNMT1 represents a potential therapeutic strategy for leukemia.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:34Inhibition of Cdk Activity
00:50Anaphase Promoting Complex